Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

 
• By Jung Won Shin
  
Desperate businessmen
Janssen Drops Hanmi's GLP-1/GCG peptide As Glycemic Control Targets Unmet

More from South Korea

More from Focus On Asia